# EDGAR Filing Document

**Accession Number:** 0001697532
**File Stem:** 0001193125-26-035507
**Filing Date:** 2026-2
**Character Count:** 8534
**Document Hash:** 3a8bc088f8cab838bcc0e2cac8765758
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-035507.hdr.sgml**: 20260203

**ACCESSION NUMBER**: 0001193125-26-035507

**CONFORMED SUBMISSION TYPE**: S-8 POS

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260203

**DATE AS OF CHANGE**: 20260203

**EFFECTIVENESS DATE**: 20260203

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Applied Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001697532
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8 POS
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-231618
- **FILM NUMBER:** 26592869

**BUSINESS ADDRESS:**
- **STREET 1:** 545 FIFTH AVENUE, SUITE 1400
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10017
- **BUSINESS PHONE:** 212-220-9226

**MAIL ADDRESS:**
- **STREET 1:** 545 FIFTH AVENUE, SUITE 1400
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10017

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Applied Therapeutics Inc.
- **DATE OF NAME CHANGE:** 20170208

**As filed with the Securities and Exchange Commission on February 3, 2026** 

**Registration No. 333-286731** 

**Registration No. 333-270767** 

**Registration No. 333-255018** 

**Registration No. 333-231618** 

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

**Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-286731** 

**Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-270767** 

**Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-255018** 

**Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-231618** 

***UNDER***

***THE SECURITIES ACT OF 1933***

## Applied Therapeutics, Inc.
**(Exact name of registrant as specified in its charter)** 

---

| | |
|:---|:---|
| **Delaware** | **81-3405262** |
| **(State or other Jurisdiction of**<br> **Incorporation or Organization)** | **(I.R.S. Employer**<br> **Identification No.)** |

---

---

| | |
|:---|:---|
| **545 Fifth Avenue, Suite 1400**<br> **New York, New York** | **10017** |
| **(Address of Principal Executive Offices)** | **(Zip Code)** |

---

**2019 Equity Incentive Plan, as Amended** 

**Restricted Stock Unit Award and Option Inducement Awards** 

**2016 Equity Incentive Plan, as Amended** 

**2019 Employee Stock Purchase Plan** 

**(Full title of the plans)** 

**James Harrison** 

**President** 

**Applied Therapeutics, Inc.** 

**545 Fifth Avenue, Suite 1400** 

**New York, New York 10017** 

**(Name and address of agent for service)** 

**(212) 220-9226** 

**(Telephone Number, including area code, of agent for service)** 

***With a copy to:***

**Michael R. Patrone** 

**Amanda J. Gill** 

**Goodwin Procter LLP** 

**620 Eighth Avenue** 

**New York, New York 10018** 

**(212) 813-8800** 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
| Non-accelerated filer | ☒ | Smaller reporting company | ☒ |
|  |  | Emerging growth company | ☐ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

------

**DEREGISTRATION OF SECURITIES** 

These Post-Effective Amendments (the "**Post-Effective Amendments**") relate to the following Registration Statements (collectively, the "**Registration Statements**") filed by Applied Therapeutics, Inc. (the "**Company**") with the Securities and Exchange Commission (the "**SEC**"):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Registration Statement No. 333-286731, filed with the SEC on
April 24, 2025, registering (i) 3,000,000 shares (the "**Inducement Shares**") of common stock, par value $0.0001 per share of the Company ()"**Common Stock** "), issuable upon the exercise of certain inducement
stock option awards subject to time-based and performance-based vesting and upon the settlement of certain restricted stock units granted on December 19, 2024, and
(ii) an aggregate of 11,104,928 shares of Common Stock, issuable pursuant to the Company's 2019 Equity Incentive Plan, as amended (the "**Plan** ").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Registration Statement No. 333-270767, filed with the SEC on
March 23, 2023, registering 3,713,943 shares of Common Stock issuable pursuant to the Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Registration Statement No. 333-255018, filed with the SEC on
April 2, 2021, registering 2,051,261 shares of Common Stock issuable pursuant to the Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Registration Statement No. 333-231618, filed with the SEC on
May 20, 2019, registering 4,710,000 shares of the Common Stock consisting of (a) 2,786,332 shares of Common Stock, issuable pursuant to the Company's 2016 Equity Incentive Plan, as amended, (b) an aggregate of 1,743,668 shares
of Common Stock, issuable pursuant to the Plan and (c) 180,000 shares of Common Stock, issuable pursuant to Company's 2019 Employee Stock Purchase Plan.

On February 3, 2026, pursuant to the Agreement and Plan of Merger, dated as of December 11, 2025 (the "**Merger Agreement**"), by and among the Company, Cycle Group Holdings Limited, a private limited company incorporated in England and Wales ("**Parent**"), and AT2B, Inc., a Delaware corporation and an indirect wholly owned subsidiary of Parent ("**Purchaser**"), Purchaser merged with and into the Company (the "**Merger**"), with the Company surviving the Merger as a private company and an indirect wholly owned subsidiary of Parent.

As a result of the transactions contemplated by the Merger Agreement, the Company has terminated all of the offerings and sales of the Company's securities pursuant to the Registration Statements. In accordance with the undertakings made by the Company in each of the Registration Statements to remove from registration, by means of a post-effective amendment, any of the securities of the Company registered under such Registration Statements which remain unsold at the termination of the offering, the Company hereby terminates the effectiveness of each Registration Statement and removes from registration, by means of these Post-Effective Amendments, all of the securities of the Company registered under the Registration Statements that remain unsold as of the date of these Post-Effective Amendments, if any. The Registration Statements are hereby amended, as appropriate, to reflect the deregistration of such securities, and the Company hereby terminates the effectiveness of each of the Registration Statements. After giving effect to these Post-Effective Amendments, there will be no remaining securities registered by the Company pursuant to the Registration Statements.

The foregoing description of the Merger, the Merger Agreement and the transactions contemplated thereby does not purport to be complete and is subject to, and qualified in its entirety by, the Merger Agreement, which is attached as Exhibit 2.1 to the Company's Current Report on Form 8-K filed with the SEC on December 12, 2025.

------

**SIGNATURES** 

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused these Post-Effective Amendments to the Registration Statements on Form S-8 to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Cambridge, Country of United Kingdom on February 3, 2026.

No other person is required to sign these Post-Effective Amendments to the Registration Statements in reliance upon Rule 478 under the Securities Act of 1933, as amended.

---

| | |
|:---|:---|
| **Applied Therapeutics, Inc.** | **Applied Therapeutics, Inc.** |
| By: | /s/ James Harrison |
| Name: | James Harrison |
| Title: | President |

---